Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants

Open access
Momozawa, Yukihide, Sasai, Rumi, Usui, Yoshiaki, Shiraishi, Kouya, Iwasaki, Yusuke, Taniyama, Yukari, Parsons, Michael T., Mizukami, Keijiro, Sekine, Yuya, Hirata, Makoto, Kamatani, Yoichiro, Endo, Mikiko, Inai, Chihiro, Takata, Sadaaki, Ito, Hidemi, Kohno, Takashi, Matsuda, Koichi, Nakamura, Seigo, Sugano, Kokichi, Yoshida, Teruhiko, Nakagawa, Hidewaki, Matsuo, Keitaro, Murakami, Yoshinori, Spurdle, Amanda B., Kubo, Michiaki · 2022 · JAMA Oncology

Abstract

Importance: The clinical importance of genetic testing of BRCA1 and BRCA2 in breast, ovarian, prostate, and pancreatic cancers is widely recognized. However, there is insufficient evidence to include other cancer types that are potentially associated with BRCA1 and BRCA2 in clinical management guidelines. Objective: To evaluate the association of BRCA1 and BRCA2 pathogenic variants with additional cancer types and their clinical characteristics in 100 914 individuals across 14 cancer types. Design, Setting, and Participants: This case-control analysis to identify cancer types and clinical characteristics associated with pathogenic variants in BRCA1 and BRCA2 included DNA samples and clinical information from 63 828 patients with 14 common cancer types and 37 086 controls that were sourced from a multi-institutional hospital-based registry, BioBank Japan, between April 2003 and March 2018. The data were analyzed between August 2019 and October 2021. Main Outcomes and Measures: Germline pathogenic variants in coding regions and 2 bp flanking intronic sequences in BRCA1 and BRCA2 were identified by a multiplex polymerase chain reaction-based target sequence method. Associations of (likely) pathogenic variants with each cancer type were assessed by comparing pathogenic variant carrier frequency between patients in each cancer type and controls. Results: A total of 65 108 patients (mean [SD] age at diagnosis, 64.1 [11.6] years; 27 531 [42.3%] female) and 38 153 controls (mean [SD] age at registration, 61.8 [14.6] years; 17 911 [46.9%] female) were included in this study. A total of 315 unique pathogenic variants were identified. Pathogenic variants were associated with P < 1 × 10-4 with an odds ratio (OR) of greater than 4.0 in biliary tract cancer (OR, 17.4; 95% CI, 5.8-51.9) in BRCA1, esophageal cancer (OR, 5.6; 95% CI, 2.9-11.0) in BRCA2, and gastric cancer (OR, 5.2; 95% CI, 2.6-10.5) in BRCA1, and (OR, 4.7; 95% CI, 3.1-7.1) in BRCA2 in addition to the 4 established cancer types. We also observed an association with 2 and 4 other cancer types in BRCA1 and BRCA2, respectively. Biliary tract, female breast, ovarian, and prostate cancers showed enrichment of carrier patients according to the increased number of reported cancer types in relatives. Conclusions and Relevance: The results of this large-scale registry-based case-control study suggest that pathogenic variants in BRCA1 and BRCA2 were associated with the risk of 7 cancer types. These results indicate broader clinical relevance of BRCA1 and BRCA2 genetic testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2022.0476

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 221

Metadata

Authors
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., Parsons, M. T., Mizukami, K., Sekine, Y., Hirata, M., Kamatani, Y., Endo, M., Inai, C., Takata, S., Ito, H., Kohno, T., Matsuda, K., Nakamura, S., Sugano, K., Yoshida, T., Nakagawa, H., Matsuo, K., Murakami, Y., Spurdle, A. B., & Kubo, M.
Venue
JAMA Oncology
Published
2022-06-01
Volume
8
Issue
6
Pages
871
ISSN
2374-2437 (ISSN-L)
OpenAlex
W4223894169
Cited by
221
References
5
FWCI
23.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. https://app.cochat.ai/papers/10.1001/jamaoncol.2022.0476
The paper
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., Parsons, M. T., Mizukami, K., Sekine, Y., Hirata, M., Kamatani, Y., Endo, M., Inai, C., Takata, S., Ito, H., Kohno, T., Matsuda, K., Nakamura, S., Sugano, K., . . . Kubo, M. (2022). Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.0476

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.